SBT8230 Antibody
SBT8230 Antibody is the antibody moiety of SBT8230, and belongs to anti-ASGR1 antibodies. SBT8230 is an ASGR1-targeted TLR8 agonist, which acts as an ASGR1-TLR8 immune-targeting antibody conjugate (ISAC). SBT8230 activates myeloid cells and induces anti-HBV immune responses. SBT8230 is applicable to research on chronic hepatitis B infection. The isotype control for SBT8230 Antibody is Human IgG1 kappa, Isotype Control (HY-P99001).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human IgG1 kappa
Human
|
TLR8 |
SBT8230 Antibody is the antibody component of SBT8230. As a liver-targeted TLR8 agonist against ASGR1, SBT8230 activates myeloid cells in hepatocyte models and induces anti-HBV immune responses and antiviral T-cell responses[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
ASGR1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
化学情報
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Gan L, et al. A High-Throughput Cell-Based Luciferase Reporter Assay for Identifying Inhibitors of ASGR1. Int J Mol Sci. 2025;26(10):4590. Published 2025 May 10. [Content Brief]
[2]. Mak LY, et al. New strategies for the treatment of chronic hepatitis B. Trends Mol Med. 2022;28(9):742-757. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
SBT8230 Antibody 関連分類
HY-P992458 関連分類
Powered by Bioz